Skip to Main Content

Paper Details

Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
Clin Pharmacol Ther
2
2014
Author NameAffiliation
Deanna L KroetzUniversity of California san francisco
  • 1 - 1

Datasets

Release 1.2